HOME ·

01093.HK

CSPC PHARMA (01093.HK): Phase I Data for SYS6002 in Advanced Cervical Cancer; Confirmed ORR Up to 35.9%
Tags：
NewTimeSpaceCSPC PHARMA01093.HK
2026-10-08
CSPC PHARMA (01093.HK): 8 trials to feature at ESMO 2026, two as LBAs
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-10-05
CSPC PHARMA (01093.HK): Efmedaglutide Alfa Phase III Data at EASD 2026
Tags：
CSPC PHARMA01093.HKInnovative Drugs
2026-09-30
CSPC PHARMA (01093.HK): JMT206 Phase Ib Obesity Trial Starts in China
Tags：
CSPC PHARMA01093.HKInnovative Drugs
2026-09-29
CSPC PHARMA (01093.HK): SYS6077 injection wins clinical trial nod
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-28
CSPC PHARMA (01093.HK): Phase III Trial of Becotatug (JMT101) plus Osimertinib Meets Primary Endpoint, Significantly Extending PFS
Tags：
NewTimeSpaceCSPC PHARMA01093.HK
2026-09-24
CSPC PHARMA (01093.HK): HB1801 Phase III Trial Starts in China
Tags：
CSPC PHARMA01093.HKPhase III Trial
2026-09-24
CSPC PHARMA (01093.HK): Phase II Trial of SYH2069 Injection for Adult Type 2 Diabetes Commences at First Site in China
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-16
CSPC PHARMA (01093.HK): SYS6010 Included in China's Breakthrough Therapy Designation List for Driver-Gene-Negative Non-Squamous NSCLC
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-15
CSPC PHARMA (01093.HK): Phase I/II Data of SYS6010 Combined with Enlangsuba Monoclonal Antibody in Previously Untreated Driver-Gene-Negative Advanced NSCLC Presented as Oral Presentation at 2026 WCLC
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-14
CSPC PHARMA (01093.HK): SYH9087, China's First Subcutaneous Rotigotine Long-acting Product, Cleared for Clinical Trials
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-09
CSPC PHARMA (01093.HK): SYH9102, World's First Ready-to-use Goserelin Extended-release Injection, Cleared for Clinical Trials in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-09-09
CSPC PHARMA (01093.HK): Innovative Chemical Drug SYH2083 Eye Drops Obtains Clinical Trial Approval in China for Dry Eye Disease
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-09-08
CSPC PHARMA (01093.HK): Phase II clinical trial of SYH2085 tablets for uncomplicated influenza in adults officially initiated in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-09-07
CSPC PHARMA (01093.HK): ADC candidate SYS6010 receives another Breakthrough Therapy designation in China for recurrent or metastatic head and neck squamous cell carcinoma
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-01
CSPC PHARMA (01093.HK): Phase I clinical trial of SYH2056 tablets for major depressive disorder officially initiated in China
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-09-01
CSPC PHARMA (01093.HK): Phase I clinical trial of SYH2092 for weight management initiated in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-09-01
CSPC PHARMA (01093.HK): Phase II Clinical Trial of SYH2069 Injection for Weight Management in Overweight or Obese Adults Launched at First Study Site in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-08-28
CSPC PHARMA (01093.HK): High-potency amylin receptor agonist SYH2092 injection approved for clinical trials in China
Tags：
CSPC PHARMA01093.HKClinical Trial
2026-08-27
CSPC PHARMA (01093.HK): SYS6090 granted FDA Fast Track designation for MSS/pMMR metastatic colorectal cancer
Tags：
CSPC PHARMA01093.HKR&D Progress
2026-08-26
123